Johnson & Johnson seeks FDA approval for CAPLYTA mania use
The filing rests on two Phase 3 trials in adults with bipolar I mania, where the company said symptoms improved versus placebo by Day 3.

Johnson & Johnson said on Nov. 19 in a press release that it filed a supplemental New Drug Application with the U.S. Food and Drug Administration for CAPLYTA, supported by two Phase 3 studies.
The request matters because CAPLYTA is not approved for manic or mixed episodes associated with bipolar I disorder; approval would make bipolar mania its fifth adult use, Johnson & Johnson said.
The company said Study 451 and Study 452 were randomized, double-blind, placebo-controlled Phase 3 trials in adults with manic episodes, with or without mixed features, associated with bipolar I disorder. Participants received CAPLYTA or placebo for three weeks.
Johnson & Johnson said both studies met their primary endpoint: change from baseline in Young Mania Rating Scale total score at Week 3. The company also said both trials met the key secondary endpoint, change from baseline in Clinical Global Impression-Severity score at Week 3.
“For people experiencing acute mania, rapid symptom improvement and tolerability are both critical treatment considerations,” John C. Reed, executive vice president, Innovative Medicine, R&D at Johnson & Johnson, said in the press release.
The company said CAPLYTA reduced manic symptoms versus placebo as early as Day 3, after two days of treatment, with improvement sustained through Week 3. It also said the drug was well tolerated, with low discontinuation rates and a safety profile consistent with prior studies.
CAPLYTA, also known as lumateperone, is already approved in adults for depressive episodes associated with bipolar I or II disorder as monotherapy or adjunctive therapy, schizophrenia, and major depressive disorder as adjunctive therapy with antidepressants, according to Johnson & Johnson.
Bipolar disorder affects an estimated 11 million U.S. adults at some point in their lives, the company said. Mania is a defining feature of bipolar I disorder and can involve elevated or irritable mood, increased energy or activity, decreased need for sleep, racing thoughts and risk-taking behavior.
The filing does not mean the FDA has approved the new use. Johnson & Johnson’s press release did not provide participant counts, absolute changes in symptom scores, confidence intervals or a regulatory decision date.
Johnson & Johnson said CAPLYTA is not approved for dementia-related psychosis and that CAPLYTA and antidepressant medicines increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially in the first few months of treatment or when the dose changes.
Source: corporate press release, Johnson & Johnson, Nov. 19, 2026
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- MTCH2 blockade reduces fat-cell formation in early lab work
- CDC counts 4,588 US measles cases in 2026
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

